Stay updated on aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays a 500 internal server error indicating the study record is temporarily unavailable. This replaces the previous content with an error message.SummaryDifference16%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision: v3.6.4 is now displayed on the page, replacing Revision: v3.6.3. This indicates a minor metadata update to the page rather than a substantive content change.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, indicating a new version of the page was published. This reflects an administrative update to the page metadata rather than a change to the study details.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous revision label. This indicates a deployment/update to the page's underlying software.SummaryDifference0.1%

- Check58 days agoChange DetectedNew help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment label formatting was updated. A recruitment-closed notice ('No longer looking for participants') was added, and the revision label updated to v3.6.0 (replacing v3.5.5).SummaryDifference0.4%

- Check65 days agoChange DetectedThe study page shows a revised metadata version from v3.5.4 to v3.5.5, indicating a minor maintenance update; no changes to the study details themselves are indicated.SummaryDifference0.1%

Stay in the know with updates to aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.